Evidence map›Paper›PMID 41430372›Full record

ArticleCommunications biology2025

AcrIIA19 binds to the WED domain and inhibits various Cas9 orthologs at multiple stages.

Gi Eob Kim, So Yeon Lee, Yong Jun Kang, Hyo Bin Jin, Hyun Ho Park

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gi Eob Kim *College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
So Yeon Lee *College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0003-0444-2079
Yong Jun Kang *College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Hyo Bin JinCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Hyun Ho ParkCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea. xrayleox@cau.ac.kr.ORCID http://orcid.org/0000-0001-9928-0847

Funding

National Research Foundation of Korea (NRF) RS-2025-02316334National Research Foundation of Korea (NRF) RS-2025-16065724
6 · The paper itself

Abstract

Anti-CRISPR (Acr) proteins are natural inhibitors of clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated protein (Cas) systems, providing valuable tools for regulating genome editing. Here, we present the crystal structure of AcrIIA19, a plasmid-encoded Type II-A CRISPR-Cas system inhibitor that targets Cas9. AcrIIA19 adopts a previously uncharacterized fold and forms a stable homodimer. Biochemical assays revealed that AcrIIA19 binds selectively to the wedge (WED) domain of Cas9, a conserved structural interface critical for single guide RNA-DNA duplex stabilization and catalysis. This interaction disrupts Cas9 activity at multiple stages, independent of the order of complex assembly. Notably, AcrIIA19 exhibits broad-spectrum inhibition across divergent Cas9 orthologs, including Streptococcus pyogenes and Staphylococcus aureus Cas9, by exploiting a conserved WED domain vulnerability. Our findings establish AcrIIA19 as a versatile Cas9 inhibitor and highlight the WED domain as a strategic target for developing species-agnostic CRISPR regulatory tools in biotechnology and therapeutic applications.

Indexed as

Bacterial ProteinsCRISPR-Associated Protein 9CRISPR-Cas SystemsCrystallography, X-RayGene EditingProtein BindingProtein DomainsRNA, Guide, CRISPR-Cas SystemsStaphylococcus aureusStreptococcus pyogenesBacterial ProteinsCRISPR-Associated Protein 9RNA, Guide, CRISPR-Cas Systems

Identifiers

PMID41430372
PMCPMC12855784

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.